Biomol Research Labs featuring ScreenWell Bioactive Lipid Library at Drug Discovery Technology show
Table of Contents
Benefits
Why lipids?
At Drug Discovery Technology 2000, BIOMOL Research Laboratories, Inc. will launch an innovative new tool for receptor screening. The Screen-Well Bioactive Lipid Library from BIOMOL will enable researchers to rapidly screen and identify ligands for orphan receptors. It has particular application in nuclear and G protein-coupled receptor research, and would enhance any pharmacological screening program for orphan receptors.
Each of the 200 bioactive lipids is supplied in solution at standard concentrations of 0.1 or 1.0 mM. The library includes lipids from the following classes: prostaglandins, thromboxanes, leukotrienes, lipoxins, HETEs, DiHETEs, hepoxilins, polyunsaturated fatty acids, cannabinoids, anandamides, platelet activating factors, sphingolipids, retinoids, vitamin D metabolites, octadecanoids, LPA, phosphatidic acids, farnesyl, and geranylgeranyl derivatives. The library includes both agonists and antagonists.
Biomol President Robert Zipkin explaining the importance of lipids in his booth at Drug Discovery Technology 2000.
Said product manager Marissa Huang, "Our Screen-Well Bioactive Lipid Library is an important aid to drug discovery researchers who are screening orphan receptors for endogenous ligands in the lipid family. Biomol has assembled this library from an extensive product line of lipid standards."
Benefits
The library includes 200 bioactive lipids pre-dissolved to standard concentrations and aliquoted into three deep-well 96-well plates. The lipid library is shipped frozen and is ready to use immediately after thawing to room temperature. According to Huang, the Screen-Well Bioactive Lipid Library will save researchers time, labor, and expense, since assembling a similar a-la-carte would be cost and labor prohibitive. "This product is also useful as as a convenient stock of bioactive lipids for use in other pharmacological applications," Huang added.
Why lipids?
Lipids aren't the first thing discovery chemists think of when looking for new drug candidates, but maybe they should. "One of the newest fads is cloning orphan receptors," explained Biomol president Robert Zipkin. "Specifically, people are interested in which endogenous ligands bind to these receptors. If you're looking at candidates, you should definitely consider lipids. Once you know how they bind, that information could lead to new drug discovery areas. For example, lipid receptor ligand information led to the newest generation of drugs for diabetes and obesity."
Biomol plans to introduce new libraries of endogenous substances for receptor screening, including an Ion Channel Ligand Library and a Neurotransmitter Library.
Visit Biomol Research at Drug Discovery Technology 2000, booth #338.
For more information: Marissa Huang, Product Manager, Biomol Research Laboratories, Inc., 5120 Butler Pike, Plymouth Meeting, PA 19462. Tel: 610-942-0430. Fax: 610-941-9252.
By Angelo DePalma
Managing Editor, Drug Discovery Online